Status:

Do Not Prescribe (DNP), Red

Decision Date:

January 2023

Comments

DNP: NICE TA850 - Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy

RED: NICE TA1122: Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer (Decision date February 2026)

 

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again